Cencora, Inc. (NYSE:COR) EVP Sells 4,127 Shares of Stock

Cencora, Inc. (NYSE:COR) EVP Elizabeth S. Campbell sold 4,127 shares of Cencora stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $268.28, for a total value of $1,107,191.56. Following the sale, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. This trade represents a 21.96 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Cencora Price Performance

Shares of COR stock opened at $274.33 on Friday. The company has a market capitalization of $53.20 billion, a P/E ratio of 39.02, a P/E/G ratio of 1.31 and a beta of 0.51. The company’s 50-day simple moving average is $253.15 and its two-hundred day simple moving average is $240.91. Cencora, Inc. has a one year low of $214.77 and a one year high of $274.93. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. Cencora’s dividend payout ratio is currently 31.29%.

Analyst Upgrades and Downgrades

A number of research firms recently commented on COR. Wells Fargo & Company boosted their target price on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. JPMorgan Chase & Co. increased their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Mizuho assumed coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective for the company. Finally, Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $280.20.

Institutional Trading of Cencora

Hedge funds have recently added to or reduced their stakes in the business. JFS Wealth Advisors LLC raised its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after purchasing an additional 46 shares in the last quarter. Banque Transatlantique SA purchased a new position in Cencora during the fourth quarter valued at approximately $29,000. SBI Securities Co. Ltd. bought a new position in Cencora in the fourth quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC lifted its holdings in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after buying an additional 69 shares during the period. Finally, Kentucky Trust Co bought a new stake in Cencora during the 4th quarter valued at $33,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.